Registration and reregistration application fees. Confirmation of final rule, remanded for further notice and comment, and response to comments.
DEA is publishing a final rule regarding the registration and reregistration fees charged to controlled substances registrants. DEA is required to charge reasonable fees relating to the registration and control of the manufacture, distribution, and dispensing of controlled substances. To address this mandate, on March 22, 1993 DEA published a final rule in the Federal Register, establishing registration fees for controlled substances registrants (58 FR 15272). Following publication of the final rule, the American Medical Association (AMA) and others filed a complaint in the United States District Court for the District of Columbia objecting to the new fees. The district court issued its final order granting the government's motion for summary judgment and disposing of all claims. The AMA appealed. The United States Court of Appeals for the District of Columbia Circuit found DEA's rulemaking to be inadequate. The appeals court remanded, without vacating, the rule to DEA, requiring the agency to provide an opportunity for meaningful notice and comment on the fee-funded components of the Diversion Control Program. DEA responded to the remand requirement through a document published in the Federal Register on December 30, 1996 (61 FR 68624). This Final Rule supplements the December 30, 1996 Federal Register document and with that document, constitutes the final rule on the Drug Diversion Control Fee Account.
D003226:Congresses as Topic; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D005249:Fees and Charges / Q000266:history / Q000331:legislation & jurisprudence*; D006077:Government Agencies; D049673:History, 20th Century; D006801:Humans; D007256:Information Systems; D007391:International Cooperation; D004364:Pharmaceutical Preparations / Q000145:classification; D014481:United States
D004364:Pharmaceutical Preparations